Add-On Benefits of Amlodipine and Thiazide in Nondiabetic Chronic Kidney Disease Stage 1/2 Patients Treated with Valsartan

Hypertension frequently requires combination therapy to attain efficient control to prevent cardiovascular diseases effectively. This study was conducted to determine which add-on treatment is better, namely calcium channel blockers or diuretics, in improving vascular damage. In 70 nondiabetic chronic kidney disease stage 1/2 patients who had been already treated with angiotensin II type 1 receptor blocker valsartan for at least 12 months, amlodipine or hydrochlorothiazide was added to their existing medication. Pulse wave velocity (PWV), intima-media thickness (IMT) of the carotid arteries, urinary albumin excretion (UAE), and 24-hour ambulatory blood pressure (BP) were determined before and 12 months after the start of add-on treatments. Add-on amlodipine and add-on hydrochlorothiazide significantly and similarly decreased 24-hour ambulatory BP by 18 and 19 mm Hg, respectively, PWV by 206 and 184 cm/s, respectively, and UAE, but did not change the IMT. The decreases in BP significantly contributed to the decreases in PWV and UAE and suggested that the decrease in serum cholesterol level brought about by add-on amlodipine also contributed to the decrease in UAE. These results suggest that 12 months of add-on treatment with either amlodipine or hydrochlorothiazide could have beneficial effects in nondiabetic chronic kidney disease stage 1/2 patients already being treated with valsartan.

[1]  H. Nandeesha,et al.  Effect of Antihypertensive Therapy on Serum Lipids in Newly Diagnosed Essential Hypertensive Men , 2009, Angiology.

[2]  T. Ogihara,et al.  Effects of Candesartan Compared With Amlodipine in Hypertensive Patients With High Cardiovascular Risks: Candesartan Antihypertensive Survival Evaluation in Japan Trial , 2008, Hypertension.

[3]  B. Davis,et al.  Clinical outcomes by race in hypertensive patients with and without the metabolic syndrome: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). , 2008, Archives of internal medicine.

[4]  G. Bakris.  Combined Therapy With a Calcium Channel Blocker and an Angiotensin II Type 1 Receptor Blocker , 2008, Journal of clinical hypertension.

[5]  M. Weir.  Risk‐Based Classification of Hypertension and the Role of Combination Therapy , 2008, Journal of clinical hypertension.

[6]  Y. Yatomi,et al.  Effectiveness of Add-On Low-Dose Diuretics in Combination Therapy for Hypertension: Losartan/Hydrochlorothiazide vs. Candesartan/Amlodipine , 2007, Hypertension Research.

[7]  S. Ito,et al.  Prevalence of chronic kidney disease (CKD) in the Japanese general population predicted by the MDRD equation modified by a Japanese coefficient , 2007, Clinical and Experimental Nephrology.

[8]  K. Çağlar,et al.  Effect of antihypertensive agents on plasma adiponectin levels in hypertensive patients with metabolic syndrome , 2007, Nephrology.

[9]  H. Pawluk,et al.  EFFECTS OF PERINDOPRIL AND HYDROCHLOROTHIAZIDE ON SELECTED INDICES OF OXIDATIVE STRESS IN THE BLOOD OF ELDERLY PATIENTS WITH ESSENTIAL HYPERTENSION , 2006, Clinical and experimental pharmacology & physiology.

[10]  G. Tsivgoulis,et al.  Common Carotid Artery Intima-Media Thickness and the Risk of Stroke Recurrence , 2006, Stroke.

[11]  P. Okin,et al.  Reductions in albuminuria and in electrocardiographic left ventricular hypertrophy independently improve prognosis in hypertension: the LIFE Study , 2006, Journal of hypertension.

[12]  G. Leoncini,et al.  Evaluation of subclinical organ damage for risk assessment and treatment in the hypertensive patient: role of microalbuminuria. , 2006, Journal of the American Society of Nephrology : JASN.

[13]  A. Zanchetti,et al.  Targeting Hypertension with Valsartan: Lessons Learned from the Valsartan/HCTZ Versus Amlodipine in Stage II Hypertensive Patients (VAST) Trial , 2006, Journal of the renin-angiotensin-aldosterone system : JRAAS.

[14]  K. Homma,et al.  Low doses of losartan and trandolapril improve arterial stiffness in hemodialysis patients. , 2005, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[15]  T. Saruta,et al.  Long-term effects of statins on arterial pressure and stiffness of hypertensives , 2005, Journal of Human Hypertension.

[16]  J. Laragh,et al.  Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial , 2004, The Lancet.

[17]  T. Saruta,et al.  Long-term effects of intensive blood-pressure lowering on arterial wall stiffness in hypertensive patients. , 2003, American journal of hypertension.

[18]  T. Saruta,et al.  Intensive Blood-Pressure Lowering Effects on Arterial Wall Stiffness in Hypertensive Patients , 2003 .

[19]  G. Mancia,et al.  Calcium Antagonist Lacidipine Slows Down Progression of Asymptomatic Carotid Atherosclerosis: Principal Results of the European Lacidipine Study on Atherosclerosis (ELSA), a Randomized, Double-Blind, Long-Term Trial , 2002, Circulation.

[20]  J. Cohn,et al.  Prognostic application of arterial stiffness: task forces. , 2002, American journal of hypertension.

[21]  T. Saruta,et al.  Fluvastatin prevents development of arterial stiffness in haemodialysis patients with type 2 diabetes mellitus. , 2002, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[22]  A. Yamashina,et al.  Validity, reproducibility, and clinical significance of noninvasive brachial-ankle pulse wave velocity measurement. , 2002, Hypertension research : official journal of the Japanese Society of Hypertension.

[23]  I. Komuro,et al.  The Relation of Pulse Wave Velocities Measured by Oscillometric and Tonometric Methods and Clinical Application Studies , 2002 .

[24]  S. T. Rahman,et al.  Effects of eprosartan versus hydrochlorothiazide on markers of vascular oxidation and inflammation and blood pressure (renin-angiotensin system antagonists, oxidation, and inflammation). , 2002, The American journal of cardiology.

[25]  D S Bell,et al.  Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. , 2000, New England Journal of Medicine.

[26]  M. Laakso,et al.  Increased risk of non‐insulin-dependent diabetes mellitus in elderly hypertensive subjects , 1994, Journal of hypertension.

[27]  H. Parving.  Excess mortality associated with diuretic therapy in diabetes mellitus. , 1992, Archives of internal medicine.

[28]  A. Krolewski,et al.  Excess mortality associated with diuretic therapy in diabetes mellitus. , 1991, Archives of internal medicine.

[29]  Y. Niwa,et al.  Induction of superoxide dismutase in leukocytes by paraquat: correlation with age and possible predictor of longevity. , 1990, Blood.